var data={"title":"Leuprolide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Leuprolide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6444?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=leuprolide-drug-information\" class=\"drug drug_general\">see &quot;Leuprolide: Drug information&quot;</a> and <a href=\"topic.htm?path=leuprolide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Leuprolide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187454\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Eligard;</li>\n      <li>Lupron Depot (1-Month);</li>\n      <li>Lupron Depot (3-Month);</li>\n      <li>Lupron Depot (4-Month);</li>\n      <li>Lupron Depot (6-Month);</li>\n      <li>Lupron Depot-Ped (1-Month);</li>\n      <li>Lupron Depot-Ped (3-Month)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187455\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eligard;</li>\n      <li>Lupron;</li>\n      <li>Lupron Depot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048192\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Hormone (Gonadotropin Hormone-Releasing Analog)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Luteinizing Hormone-Releasing Hormone Analog</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048184\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=leuprolide-drug-information\" class=\"drug drug_general\">see &quot;Leuprolide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central precocious puberty (CPP):</b> <b>Note:</b> Prior to initiation of therapy, diagnostic confirmation is necessary and baseline measurements/levels of luteinizing hormone (LH) (basal or stimulated with a gonadotropin-releasing hormone [GnRH] analog), sex steroids, bone age assessment (versus chronological age), and growth parameters (height and weight measurements).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years: <b>Note: </b>Consider discontinuing leuprolide therapy at the appropriate time for the onset of puberty</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Depot Formulations (IM): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lupron Depot-Ped (monthly formulation):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: Initial: IM: 0.2 to 0.3 mg/kg/dose every 4 weeks; titrate to response (Carel 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-band, fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&le;25 kg: Initial: IM: 7.5 mg every 4 weeks; titrate dose in 3.75 mg increments every 4 weeks until clinical or laboratory tests indicate adequate suppression</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;25 to 37.5 kg: Initial: IM: 11.25 mg every 4 weeks; titrate dose in 3.75 mg increments every 4 weeks until clinical or laboratory tests indicate adequate suppression</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;37.5 kg: Initial: IM: 15 mg every 4 weeks; titrate dose in 3.75 mg increments every 4 weeks until clinical or laboratory tests indicate adequate suppression</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lupron Depot-Ped (3-month formulation): 11.25 mg or 30 mg every 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Short</i>\n      <i>-acting formulation (SubQ): </i>Leuprolide acetate 5 mg/mL solution: SubQ: Initial: 50 <b>mcg</b>/kg/dose once daily; may titrate dose upward by 10 <b>mcg</b>/kg/day if suppression of ovarian or testicular steroidogenesis is not achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endometriosis: </b>Post-menarche Adolescents: Limited data available in ages &lt;18 years: <b>Note:</b> Due to ongoing growth and bone maturation in adolescents, initial therapy with leuprolide should be in combination with norethindrone (add-back therapy) and patients should also be supplemented with calcium and vitamin D (Laufer 2008); if retreatment for an additional 6 months is necessary, concomitant norethindrone should be used. Based on experience in adults, retreatment is not recommended for longer than one additional 6-month course.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot (monthly formulation): IM: 3.75 mg every month for up to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot (3-month formulation): IM: 11.25 mg every 3 months for up to 2 doses (6 months total duration of treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leuprolide (GnRHa) Stimulation Test (Female):</b> Limited data available: Children &ge;2 years: Leuprolide acetate 5 mg/mL solution: SubQ: 20 <b>mcg</b>/kg once; measure LH and FSH at baseline and after administration (usually two spaced measurements &le;120 minutes [eg, 30 and 60 minutes <b>or</b> 60 and 120 minutes]) (Houk 2008; Sathasivam 2010; Sathasivam 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uterine leiomyomata (fibroids):</b> Adolescents &ge;18 years: <b>Note:</b> Use in combination with iron supplementation for concurrent anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot (monthly formulation): IM: 3.75 mg every month for up to 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot (3-month formulation): IM: 11.25 mg as a single injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Advanced prostate cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lupron Depot 7.5 mg (monthly): 7.5 mg every month <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lupron Depot 22.5 mg (3 month): 22.5 mg every 12 weeks <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lupron Depot 30 mg (4 month): 30 mg every 16 weeks <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lupron Depot 45 mg (6 month): 45 mg every 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Eligard: 7.5 mg monthly <b>or</b> 22.5 mg every 3 months <b>or</b> 30 mg every 4 months <b>or</b> 45 mg every 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Leuprolide acetate 5 mg/mL solution: 1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endometriosis:</b> Initial therapy may be with leuprolide alone or in combination with norethindrone; if re-treatment for an additional 6 months is necessary, concomitant norethindrone should be used. Re-treatment is not recommended for longer than one additional 6-month course.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot: IM: 3.75 mg every month for up to 6 months <b>or </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot-3 month: IM: 11.25 mg every 3 months for up to 2 doses (6 months total duration of treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uterine leiomyomata (fibroids):</b> IM (in combination with iron):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot: 3.75 mg every month for up to 3 months <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lupron Depot-3 month: 11.25 mg as a single injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187429\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/0.2 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intramuscular, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot (1-Month): 7.5 mg [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot (6-Month): 45 mg [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intramuscular, as acetate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot (1-Month): 3.75 mg [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot (3-Month): 11.25 mg, 22.5 mg [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot (4-Month): 30 mg [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot-Ped (1-Month): 7.5 mg, 11.25 mg, 15 mg [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot-Ped (3-Month): 30 mg (Ped), 11.25 mg (Ped) [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eligard: 7.5 mg, 22.5 mg, 30 mg, 45 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187414\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50133906\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lupron Injection: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019010s038lbl.pdf#page=27&amp;token=Fd/xF91MQ1mzFjjV1nOlWXGbbnJtFM9MrsRSaj/LWrGzP1N2V7GbNUvcv7NMZQTDOsGfSPAwB5/HtUyEvs2HU6b+6G36+VXoe+7oLvdD2AiXgOFAWuFIIrwhWlgBtzmj&amp;TOPIC_ID=12545\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019010s038lbl.pdf#page=27</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lupron Depot-Ped: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020263s042lbl.pdf#page=20&amp;token=2QXLb87w3r3j/pheAakwmZ1olN9pY58DolVFMMNBT6AKFlqqMevtqHHv9VVHznXUa2jvCqOqQCiCqvtHBQLlN5dJA4PDOaw1eIl4bOMhJlwcdncpZ2XUAbB9VTC2kI2z&amp;TOPIC_ID=12545\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020263s042lbl.pdf#page=20</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048195\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Do not administer IV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (Lupron Depot, Lupron Depot-Ped): Administer as a single injection into the gluteal area, anterior thigh, or deltoid; rotate administration site periodically. Reconstituted solution does not contain preservatives and should be used immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Leuprolide acetate 5 mg/mL solution: Administer undiluted into areas on the arm, thigh, or abdomen; rotate injection site. If an alternate syringe from the manufacturer-provided syringe is required, insulin syringes should be used</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Eligard: Vary injection site; choose site with adequate subcutaneous tissue (eg, upper or midabdomen, upper buttocks); avoid areas that may be compressed or rubbed (eg, belt or waistband)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132789\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (when dosage form allows) closed system transfer devices (CSTDs) for compounding. Double gloving and a gown are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187449\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eligard: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Allow to reach room temperature prior to using. Once outside the refrigerator, the kit may be stored (in its original packaging) at 15&deg;C to 30&deg;C (59&deg;F to 86 &deg;F) for up to 8 weeks prior to mixing and administration. Once mixed, must be administered within 30 minutes (discard if not used within 30 minutes).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lupron Depot, Lupron Depot-Ped: Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Upon reconstitution, the suspension does not contain a preservative and should be used immediately; discard if not used within 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leuprolide acetate 5 mg/mL solution: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and store vial in carton until use. Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048194\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of precocious puberty (Lupron Depot-Ped: FDA approved in children ages &ge;2 years); management of endometriosis (Lupron Depot: FDA approved in ages &ge;18 years); treatment of uterine leiomyomata (fibroids) (Lupron Depot: FDA approved in ages &ge;18 years); palliative treatment of advanced prostate carcinoma (Eligard, Lupron Depot, leuprolide solution generic: FDA approved in adults); has also been used as a gonadotropin-releasing hormone analog (GnRHa) stimulation test in female children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187483\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot (1-month or 3-month formulation) may be confused with Lupron Depot-Ped (1-month or 3-month formulation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lupron Depot-Ped is available in two formulations, a 1-month formulation and a 3-month formulation. Both formulations offer an 11.25 mg strength which may further add confusion.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187480\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Children </b> (based on 1-month and 3-month pediatric formulations combined)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Vasodilation </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Emotional lability, headache, mood changes, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris, seborrhea, skin rash (including erythema multiforme)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginal discharge, vaginal hemorrhage, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rare but important or life-threatening: Abnormal gait, alopecia, arthralgia, asthma, body odor, bradycardia, cervix disease, decreased visual acuity, depression, dysmenorrhea, dysphagia, epistaxis, excessive crying, feminization, gingivitis, goiter, growth suppression, gynecomastia, hirsutism, hyperhidrosis, hyperkinesia, hypersensitivity reaction, hypertension, infection, leukoderma, myopathy, obesity, peripheral edema, personality disorder, precocious puberty, purpura, skin striae, syncope, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Adults: </b>\n      <b>Note:</b> For prostate cancer treatment, an initial rise in serum testosterone concentrations may cause &ldquo;tumor flare&rdquo; or worsening of symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction during the first 2 weeks. Similarly, an initial increase in estradiol levels, with a temporary worsening of symptoms, may occur in women treated with leuprolide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Delayed release formulations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Angina pectoris, atrial fibrillation, bradycardia, cardiac arrhythmia, cardiac failure, edema, hypertension, hypotension, palpitations, syncope, tachycardia, thrombophlebitis (deep)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Agitation, anxiety, confusion, delusions, dementia, depression, dizziness, fatigue, fever, headache, insomnia, nervousness, neuropathy, ostealgia, pain, paralysis, paresthesia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris, allergic skin reaction, alopecia, cellulitis, diaphoresis, hair disease, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Decreased libido, decreased serum bicarbonate, dehydration, gynecomastia, hirsutism, hot flash, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyperuricemia, hypoalbuminemia, hypocholesterolemia, hypoproteinemia, increased lactate dehydrogenase, increased prostatic acid phosphatase, menstrual disorder, weight changes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Anorexia, change in bowel habits, constipation, diarrhea, dysphagia, eruction, gastric ulcer, gastroenteritis, gastrointestinal disease, gastrointestinal hemorrhage, intestinal obstruction, nausea and vomiting, peptic ulcer</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Balanitis, bladder spasm, dysuria, erectile dysfunction, genitourinary complaint, hematuria, impotence, lactation, mastalgia, nocturia, penile disease, testicular atrophy, testicular disease, testicular pain, urinary incontinence, urinary retention, urinary tract infection, urinary urgency, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, bruise, change in platelet count (increased), decreased hemocrit, decreased hemoglobin, decreased prostatic acid phosphatase, ecchymoses, eosinophilia, leukopenia, lymphadenopathy, neoplasm </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, hepatomegaly, increased serum AST, prolonged partial thromboplastin time, prolonged prothrombin time</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Burning sensation at injection site (transient), erythema at injection site, injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, myalgia, neuromuscular disease, pathological fracture, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Decreased urine specific gravity, increased blood urea nitrogen, increased serum creatinine, increased urine specific gravity, polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough, dyspnea, emphysema, epistaxis, flu-like symptoms, hemoptysis, increased bronchial secretions, pleural effusion, pulmonary edema, respiratory tract disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Immediate release formulation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiac failure, ECG changes, heart murmur, hypertension, myocardial infarction, peripheral edema, pulmonary embolism, syncope, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety, depression, dizziness, headache, insomnia, fatigue, fever, nervousness, ostealgia, pain, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: decreased libido, diabetes mellitus, goiter, gynecomastia, hot flash, hypercalcemia, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Alopecia, dermatitis, hyperpigmentation, pruritus, skin lesion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Anorexia, constipation, diarrhea, dysphagia, diarrhea, dysphagia, gastrointestinal hemorrhage, nausea and vomiting, peptic ulcer, rectal polyps </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Bladder spasm, decreased testicular size, dysuria, hematuria, impotence, incontinence, mastalgia, testicular pain, urinary frequency, urinary tract infection, urinary tract obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, bruise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Hematuria, increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough, dyspnea, pneumonia, pulmonary fibrosis </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever, inflammation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Children and Adults:</b> <i>Any formulations:</i> Rare but important or life-threatening: Abscess at injection site, anaphylaxis, anaphylactoid reaction, asthma, bone fracture (spine), cerebrovascular accident, convulsions, coronary artery disease, decreased white blood cell count, diabetes mellitus, fibromyalgia syndrome (arthralgia/myalgia, headaches, GI distress), hemoptysis, hepatic injury, hepatic insufficiency, hepatotoxicity, hyperuricemia, hypokalemia, hypoproteinemia, induration at injection site, interstitial pulmonary disease, leukocytosis, myocardial infarction, osteopenia, paralysis, penile swelling, peripheral neuropathy, pituitary apoplexy (cardiovascular collapse, mental status altered, ophthalmoplegia, sudden headache, visual changes, vomiting), prolonged QT interval on ECG, prostate pain, pulmonary embolism, pulmonary infiltrates, retroperitoneal fibrosis (pelvic), seizure, skin photosensitivity, suicidal ideation (rare), tenosynovitis (symptoms), thrombocytopenia, transient ischemic attacks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187436\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to leuprolide, GnRH, GnRH-agonist analogs, or any component of the formulation; women who are or may become pregnant; breastfeeding (Lupron Depot 3.75 mg [monthly] and Lupron Depot 11.25 mg [3-month]); undiagnosed abnormal vaginal bleeding (Lupron Depot 3.75 mg [monthly] and Lupron Depot 11.25 mg [3-month]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lupron Depot 22.5 mg, 30 mg, and 45 mg and Eligard (all strengths) are also not indicated for use in women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187418\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abnormal menses: Females treated for precocious puberty may experience menses or spotting during the first 2 months of treatment; notify health care provider if bleeding continues after the second month.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). Sudden cardiac death and stroke have been reported in men receiving GnRH agonists. ADT may prolong the QT/QTc interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QTc prolongation, congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients with medications known to prolong the QT interval, or with preexisting cardiac disease. Consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone density: Has been reported when used for &ge;6 months. Use caution in patients with additional risk factors for bone loss (eg, chronic alcohol use, corticosteroid therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endometriosis: Exacerbation of endometriosis or uterine leiomyomata may occur initially.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Diabetes and/or worsening of glycemic control have been reported in men receiving GnRH agonists. Monitor blood glucose and/or glycosylated hemoglobin (HbA<sub>1c</sub>) as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric events: Psychiatric events have been described with GnRH agonists, including leuprolide; symptoms of emotional lability, irritability, impatience, anger, and aggression have been reported in postmarketing accounts. Monitor for development or worsening of psychiatric symptoms. Use with caution in patients with a history of psychiatric illness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Convulsions have been observed in postmarketing reports in patients receiving GnRH agonists, including leuprolide; patients affected included both those with and without a history of cerebrovascular disorders, CNS anomalies or tumors, epilepsy, seizures, and those on concomitant medications which may lower the seizure threshold (eg, bupropion, SSRIs). If seizures occur, manage accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal cord compression: Has been reported when used for prostate cancer; closely observe patients for weakness and paresthesias in first few weeks of therapy. Observe patients with metastatic vertebral lesions closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor flare: Transient increases in testosterone (~50% above baseline) can lead to tumor flare, bone pain, hematuria, bladder outlet obstruction and neuropathy in prostate cancer patients during the first few weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract obstruction: Has been reported when used for prostate cancer; closely observe patients for urinary tract obstruction and hematuria in first few weeks of therapy. Observe patients with urinary obstruction closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer: Androgen deprivation therapy may increase the risk for cardiovascular disease, diabetes, insulin resistance, obesity, alterations in lipids, and fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concomitant drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depot formulations: Vehicle used in injectable (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale). Due to different release properties, combinations of dosage forms or fractions of dosage forms should not be interchanged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eligard Atrigel delivery system: The Atrigel delivery system is a nongelatin-based, biodegradable, polymer matrix.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Breast cancer: The American Society of Clinical Oncology (ASCO) Guideline Update on Ovarian Suppression for Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer (Burstein 2016) recommends that premenopausal women with higher-risk disease receive ovarian suppression (in addition to adjuvant endocrine therapy), although lower-risk patients should not; premenopausal women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should also receive ovarian suppression (in addition to endocrine therapy). Additionally, women with stage I or II breast cancers at higher risk of recurrence who might consider chemotherapy may be offered ovarian suppression (in addition to endocrine therapy). Women with stage 1 disease which does not require chemotherapy should receive endocrine therapy, but not ovarian suppression. Likewise, women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy, but not ovarian suppression. Guidelines from ASCO for Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer (Rugo 2016) recommend that premenopausal women with ER-positive metastatic breast cancer start ovarian suppression, preferably in combination with hormonal therapy. While premenopausal patients without prior hormone therapy exposure can be treated with tamoxifen, or ovarian suppression, or ablation alone, combination therapy is preferred. In metastatic breast cancer, ovarian suppression with GnRH agonists or ablation with oophorectomy appear to achieve similar results.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Prostate cancer: Guidelines from the American Society of Clinical Oncology (ASCO) for hormonal management of advanced prostate cancer which is androgen-sensitive (Loblaw 2007) recommend either orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonists as initial treatment for androgen deprivation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26021978\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">An increase in pubertal signs and symptoms may occur in the first 2 to 4 weeks of therapy due to the initial stimulatory effect of leuprolide before suppression occurs. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299584\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6004203\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12545&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187425\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187440\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events were observed in animal reproduction studies. Pregnancy must be excluded prior to the start of treatment. Although leuprolide usually inhibits ovulation and stops menstruation, contraception is not ensured and a nonhormonal contraceptive should be used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048191\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Precocious puberty:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: GnRH testing (blood LH and FSH levels), measurement of height and bone age every 6 to 12 months, testosterone in males and estradiol in females (IM [monthly] and SubQ formulations: 1 to 2 months after initiation of therapy or with dosage change; IM [3 month] formulation: 2 to 3 months after initiation of therapy, month 6, and as clinically indicated thereafter); Tanner staging</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Consensus recommendation: Tanner stage and growth (growth velocity, height) every 3 to 6 months and bone age periodically. Routine or random stimulated measurements of gonadotropins or sex steroids may be used, particularly if suboptimal response; however, use of FSH levels not typically used (Carel 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents (eg, endometriosis): Monitor growth parameters (height, weight, z-scores), BMD (Laufer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Prostate carcinoma: LH and FSH levels, serum testosterone (~4 weeks after initiation of therapy), PSA; weakness, paresthesias, and urinary tract obstruction in first few weeks of therapy. Screen for diabetes (blood glucose and HbA<sub>1c</sub>) and cardiovascular risk prior to initiating and periodically during treatment. Consider periodic monitoring of electrocardiograms and electrolytes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187417\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Leuprolide, is an agonist of gonadotropin releasing hormone (GnRH) receptors. Acting as a potent inhibitor of gonadotropin secretion, leuprolide produces an initial increase in luteinizing hormone (LH) and follicle stimulating hormone (FSH), which leads to a transient increase (5 to 12 days [Cook 2000]) in testosterone and dihydrotestosterone (in males) and estrone and estradione (in premenopausal females). Continuous leuprolide administration then results in suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. In males, testosterone levels are reduced to below castrate levels. Leuprolide may also have a direct inhibitory effect on the testes, and act by a different mechanism not directly related to reduction in serum testosterone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187435\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Following transient increase, testosterone suppression occurs in ~2 to 4 weeks of continued therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of therapeutic suppression for precocious puberty: Leuprolide: 2 to 4 weeks; Leuprolide depot: 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Males: V<sub>d</sub>: 27 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 43% to 49%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Major metabolite, pentapeptide (M-1)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;5% as parent and major metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187439\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Eligard Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (1): $542.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.5 mg (1): $1,626.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $2,168.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (1): $3,252.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lupron Depot (1-Month) Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.75 mg (1): $1,469.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (1): $1,750.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lupron Depot (3-Month) Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11.25 mg (1): $4,408.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.5 mg (1): $5,252.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lupron Depot (4-Month) Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $7,003.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lupron Depot (6-Month) Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (1): $10,505.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lupron Depot-Ped (1-Month) Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (1): $1,767.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11.25 mg (1): $3,209.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $3,534.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lupron Depot-Ped (3-Month) Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11.25 mg (ped) (1): $9,627.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (ped) (1): $10,603.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187441\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Divalin (ID);</li>\n      <li>Eligard (AU, BG, CR, CY, DE, DK, DO, EE, FR, GT, HK, HN, HR, ID, IE, IS, LB, LT, LV, MT, MY, NI, NZ, PA, PH, PL, QA, RO, SG, SI, SK, SV, TH, TR, VN);</li>\n      <li>Elihard (UA);</li>\n      <li>Enanton Depot (DK, FI, NO, SE);</li>\n      <li>Enantone (AT, DE, FR);</li>\n      <li>Enantone Depot (IT);</li>\n      <li>Enantone LP (TH);</li>\n      <li>Enantone SR (CN, HK);</li>\n      <li>Endrolin (ID);</li>\n      <li>Leoprostin (EC);</li>\n      <li>Leuplin (KR);</li>\n      <li>Leuplin Depot (TW);</li>\n      <li>Leuplin Pro (JP);</li>\n      <li>Leuplin SR (JP);</li>\n      <li>Lorelin (MX, PK);</li>\n      <li>Lucrin (AU, MY, NZ, RU, SG, TR, VN);</li>\n      <li>Lucrin Depot (AU, BE, CH, CR, CZ, DK, GT, HN, IL, KR, MX, NI, NZ, PA, PL, RO, SG, SV, TR);</li>\n      <li>Lucrin PDS (MY);</li>\n      <li>Luphere Depot (PH, VN);</li>\n      <li>Lupride (IN, LK);</li>\n      <li>Lupride Depot (IN);</li>\n      <li>Lupro (TW);</li>\n      <li>Luprolex (PH);</li>\n      <li>Luprolex Depot (PH);</li>\n      <li>Lupron (AR, BH, BM, BR, BS, CL, CO, EC, GY, JM, JO, NL, PR, PY, QA, SR, TT, UY, VE);</li>\n      <li>Lupron Depot (AE, AR, BB, BH, BR, CL, EC, KW, PE, PY, SA, UY, VE);</li>\n      <li>Lupron SC (CO, PE);</li>\n      <li>Lutkate (GB);</li>\n      <li>Lutrate Depot (AT);</li>\n      <li>Prelar Depot (MX);</li>\n      <li>Procren Depot (DK, FI, NO, SE);</li>\n      <li>Procrin (ES);</li>\n      <li>Prostap (GB, IE);</li>\n      <li>Tapros (ID);</li>\n      <li>Tapros 3M (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. <i>J Clin Oncol</i>. 2016;34(14):1689-1701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26884586/pubmed\" target=\"_blank\" id=\"26884586\">26884586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carel JC, Eugster EA, Rogol A, et al, &quot;Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children,&quot; <i>Pediatrics</i>, 2009, 123(4):e752-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19332438/pubmed\" target=\"_blank\" id=\"19332438\">19332438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. <i>Oncologist</i>. 2000;5(2):162-168. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/10794807/pubmed\" target=\"_blank\" id=\"10794807\">10794807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eligard (leuprolide) [prescribing information]. Fort Collins, CO: Tomar; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houk CP, Kunselman AR, Lee PA. The diagnostic value of a brief GnRH analogue stimulation test in girls with central precocious puberty: a single 30-minute post-stimulation LH sample is adequate. <i>J Pediatr Endocrinol Metab</i>. 2008;21(12):1113-1118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19189683/pubmed\" target=\"_blank\" id=\"19189683\">19189683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kappy MS, Stuart T, and Perelman A, &ldquo;Efficacy of Leuprolide Therapy in Children With Central Precocious Puberty,&rdquo; <i>Am J Dis Child</i>, 1988, 142(10):1061-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/3140654/pubmed\" target=\"_blank\" id=\"3140654\">3140654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laufer MR. Current approaches to optimizing the treatment of endometriosis in adolescents. <i>Gynecol Obstet Invest</i>. 2008;66 Suppl 1:19-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/18936548/pubmed\" target=\"_blank\" id=\"18936548\">18936548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee PA and Page JG, &ldquo;Effects of Leuprolide in the Treatment of Central Precocious Puberty,&rdquo; <i>J Pediatr</i>, 1989, 114(2):321-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/2492599 /pubmed\" target=\"_blank\" id=\"2492599 \">2492599 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leuprolide acetate injection [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo; <i>Circulation</i>, 2010, 121:831-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loblaw DA, Virgo KS, Nam R, et al. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2006 Update of an American Society of Clinical Oncology Practice Guideline. <i>J Clin Oncol.</i> 2007; 25(12):1596-1605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17404365/pubmed\" target=\"_blank\" id=\"17404365\">17404365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lupron Depot 1-month 7.5 mg, 3-month 22.5 mg, 4-month 30 mg, 6-month 45 mg (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lupron Depot 3.75 mg (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lupron Depot 3-month 11.25 mg (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lupron Depot-PED (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. <i>J Clin Oncol</i>. 2016 May 23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/27217461/pubmed\" target=\"_blank\" id=\"27217461\">27217461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sathasivam A, Garibaldi L, Shapiro S, et al. Leuprolide stimulation testing for the evaluation of early female sexual maturation. <i>Clin Endocrinol (Oxf)</i>. 2010;73(3):375-381. doi: 10.1111/j.1365-2265.2010.03796.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/20184599/pubmed\" target=\"_blank\" id=\"20184599\">20184599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sathasivam A, Rosenberg HK, Shapiro S, et al. Pelvic ultrasonography in the evaluation of central precocious puberty: comparison with leuprolide stimulation test. <i>J Pediatr</i>. 2011;159(3):490-495. doi: 10.1016/j.jpeds.2011.02.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/21489559/pubmed\" target=\"_blank\" id=\"21489559\">21489559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaka T, Niimi H, Matsuo N, et al, &quot;Results of Long-Term Follow-Up After Treatment of Central Precocious Puberty With Leuprorelin Acetate: Evaluation of Effectiveness of Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty,&quot; <i>J Clin Endocrinol Metab</i>, 2005, 90(3):1371-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/15598675/pubmed\" target=\"_blank\" id=\"15598675\">15598675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12545 Version 152.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187454\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187455\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048192\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048184\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187429\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187414\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50133906\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048195\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132789\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187449\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048194\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187483\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187480\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187436\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187418\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26021978\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299584\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6004203\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187425\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187440\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048191\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187417\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187435\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187439\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187441\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12545|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=leuprolide-drug-information\" class=\"drug drug_general\">Leuprolide: Drug information</a></li><li><a href=\"topic.htm?path=leuprolide-patient-drug-information\" class=\"drug drug_patient\">Leuprolide: Patient drug information</a></li></ul></div></div>","javascript":null}